该HEARTS合作伙伴论坛支持实施HEARTS治疗和控制高血压
Taskeen Khan1, Andrew E Moran2,3, Pablo Perel4,5
1Department of Non-communicable Diseases, World Health Organization, Geneva, Switzerland.
Frontiers in public health
|August 9, 2023
概括
全球心脏倡议由世卫组织和CDC领导,通过初级卫生保健解决心血管疾病 (CVD) 和高血压问题. 这种公共卫生方法已经成功治疗了700多万名高血压患者,证明了其可行性和在普遍医疗覆盖中的作用.
科学领域:
- 公共卫生 公共卫生
- 心血管医学 心血管医学
- 全球卫生倡议全球卫生倡议
背景情况:
- 心血管疾病 (CVD),包括缺血性心脏病 (IHD) 和中风,是全球死亡和残疾的主要原因.
- 高血压是心血管疾病的最重要的可预防风险因素,每年导致数百万人死亡.
- 全球心脏倡议是由世卫组织和疾病预防控制中心发起的,旨在支持各国预防和控制心血管疾病.
研究的目的:
- 概述HEARTS技术包及其在初级医疗保健层面管理高血压和心血管疾病风险因素的公共卫生方法.
- 突出HEARTS合作伙伴论坛在协调11个国际组织的作用,以支持国家一级的CVD预防工作.
- 展示HEARTS方法的可行性和可接受性及其作为通用健康覆盖的途径的潜力.
主要方法:
- 在初级医疗保健层面实施HEARTS技术包,这是全球HEARTS倡议的核心组成部分.
- 使用一种简单的算法方法来治疗高血压.
- 通过HEARTS合作伙伴论坛促进合作和支持,涉及多个国际组织.
主要成果:
- 已有超过700万个人使用HEARTS方法治疗高血压.
- "心脏"倡议已经证明了针对心血管疾病风险因素管理的公共卫生战略的可行性和可接受性.
- 通过HEARTS的高血压管理显示出作为实现全民健康覆盖的关键干预措施的潜力.
结论:
- 在全球推进心血管疾病预防和控制方面,HEARTS合作伙伴论坛至关重要.
- 论坛需要采取更加结构化的方法,包括明确的目标和报告,以加强合作和影响.
- HEARTS倡议有助于减少心脏病死亡率和实现可持续发展目标 (SDGs).
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:28Hypertension I: Introduction
16
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
16